Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00447564 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of Probuphine in the Treatment of Opioid Dependence
A Phase 3 study, sponsored by Titan Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 163
- Enrollment target
NCT00447564: Completed Phase 3 study, sponsored by Titan Pharmaceuticals.
NCT00447564 is a Phase 3 study that has completed, run by Titan Pharmaceuticals. The registered enrollment target is 163 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (79% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00447564, a Phase 3 study, has completed, sponsored by Titan Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 163 participants
- Enrollment target
Study Summary
Buprenorphine (BPN) is an approved treatment for opioid dependence, however, in taking oral tablets, patients experience withdrawal and cravings when the variable BPN levels in the blood are low. Probuphine is an implant placed just beneath the skin that contains BPN. It is designed to provide 6 months of stable BPN blood levels. This study will test the safety and efficacy of Probuphine in the treatment of patients with opioid dependence.
Interventions
- DRUG placebo
- DRUG Probuphine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 163 participants |
| Start Date | 2006-10 |
| Est. Completion | 2008-07 |
| Phase | Phase 3 |
What the finished NCT00447564 record still lists
NCT00447564 is an interventional study that assigns participants to a tested intervention. The registered 163 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (79% lower).
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00447564 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00447564 about?
NCT00447564 is a clinical study titled "Safety and Efficacy of Probuphine in the Treatment of Opioid Dependence". Buprenorphine (BPN) is an approved treatment for opioid dependence, however, in taking oral tablets, patients experience withdrawal and cravings when the variable BPN levels in the blood are low. Probuphine is an implant placed just beneath the skin that contains BPN. It is designed to provide 6 mon...
What is the current status of trial NCT00447564?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 163 participants. The study started on 2006-10. Estimated completion is 2008-07.
What interventions are being tested in trial NCT00447564?
The interventions under investigation include: placebo (DRUG), Probuphine (DRUG).
Who is sponsoring clinical trial NCT00447564?
This trial is sponsored by Titan Pharmaceuticals, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00447564's enrollment target sits among peer trials
163 1471st of 2000 higher than 527 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03180268 · 163 participants · Phase 3
Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery
- NCT04862221 · 163 participants · Phase 2
TReatment for ImmUne Mediated PathopHysiology
- NCT05702229 · 163 participants · Phase 2
Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
- NCT06137118 · 163 participants · Phase 1
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia